Incyte | INCY - Loan Capital

Stock Price
97.80
Daily Change
2.08 2.17%
Monthly
8.27%
Yearly
61.84%
Q2 Forecast
92.62

Incyte reported $29.41M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agenus USD 169.66M 146.06M Dec/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Gilead Sciences USD 22.13B 6M Dec/2025
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
MacroGenics USD 70M 256K Dec/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 29.59B 5.35B Dec/2025
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025